Want to see CPMD full AI Analyst Report?
CPMD Stock Chart & Stats
$0.01
<$0.01(11.76%)
At close: 4:00 PM EST
$0.01
<$0.01(11.76%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume41.77K
Average Volume (3M)N/A
Market Cap
$1.42M
Enterprise Value$22.67M
Total Cash (Recent Filing)$633.00
Total Debt (Recent Filing)$20.97M
Price to Earnings (P/E)―
Beta-0.30
Next Earnings
May 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding678,501,400
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)-0.11
Price to Sales (P/S)2.53
P/FCF Ratio-4.34
Enterprise Value/Market Cap15.91
Enterprise Value/Revenue13.70
Enterprise Value/Gross Profit-11.38
Enterprise Value/Ebitda-2.76
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained double-digit TTM revenue growth and acceleration to $1.65M indicate expanding commercial traction and market adoption. Over a 2-6 month horizon this momentum supports scaling efforts, provides a foundation to leverage fixed costs, and improves the odds of achieving operating leverage if sustained.
Improving Cash BurnMaterial reduction in operating and free cash outflows suggests management has tightened cost controls or improved operations. This durable improvement lowers near-term financing needs, extends runway, and increases probability the company can reach sustainable cash flow without immediate dilutive capital raises.
Debt Reduction TrendA decline in total debt versus the prior annual period signals early deleveraging and potential easing of interest and covenant pressure. If continued, this trend improves financial flexibility, reduces fixed financing costs, and strengthens the company's ability to invest in product or commercial initiatives.
Bears Say
Deeply Negative EquityDeeply negative equity is a durable capital-structure impairment that increases insolvency and refinancing risk. It constrains access to non-dilutive financing, raises lender and supplier concerns, and elevates the probability of future equity dilution or restructuring if operating fundamentals do not rapidly improve.
Negative Gross Profit And Large LossesNegative gross profit means unit economics are structurally unprofitable today, not just below operating line. Large TTM losses of ~$10.8M indicate the core business has yet to demonstrate sustainable margins, requiring fundamental changes to pricing, cost structure, or product mix to become viable long-term.
Ongoing Negative Cash Flow ReliancePersistent negative operating and free cash flow creates a structural dependency on external capital. With a stressed balance sheet and negative equity, future fundraising may be costly or dilutive, limiting strategic options and making long-term execution contingent on securing financing or achieving rapid operational turnaround.
Cannapharmarx News
CPMD FAQ
What was Cannapharmarx Inc’s price range in the past 12 months?
Currently, no data Available
What is Cannapharmarx Inc’s market cap?
Cannapharmarx Inc’s market cap is $1.42M.
When is Cannapharmarx Inc’s upcoming earnings report date?
Cannapharmarx Inc’s upcoming earnings report date is May 25, 2027 which is in 304 days.
How were Cannapharmarx Inc’s earnings last quarter?
Cannapharmarx Inc released its earnings results on May 19, 2026. The company reported -$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.001.
Is Cannapharmarx Inc overvalued?
According to Wall Street analysts Cannapharmarx Inc’s price is currently Overvalued.
Does Cannapharmarx Inc pay dividends?
Cannapharmarx Inc does not currently pay dividends.
What is Cannapharmarx Inc’s EPS estimate?
Cannapharmarx Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cannapharmarx Inc have?
Cannapharmarx Inc has 678,501,400 shares outstanding.
What happened to Cannapharmarx Inc’s price movement after its last earnings report?
Cannapharmarx Inc reported an EPS of -$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cannapharmarx Inc?
Currently, no hedge funds are holding shares in CPMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cannapharmarx Inc
CannaPharmaRX, Inc. is a Canadian enterprise actively involved in the cannabis sector. The company focuses on identifying, acquiring, and developing diverse projects for cultivating cannabis. Founded in 1998, its main offices are located in Calgary, Canada.
Tilray
―
IM Cannabis Corp
―
―
Incannex Healthcare Limited Sponsored ADR
―
Akanda Corp
―